Nanobiotix S.A. (NANO.PA)
EUR 3.48
(1.93%)
EUR 3.48
(1.93%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 30.05 Million EUR | 529.36% |
| 2022 | 4.77 Million EUR | 47660.0% |
| 2021 | 10 Thousand EUR | -80.0% |
| 2020 | 50 Thousand EUR | -26.47% |
| 2019 | 68 Thousand EUR | -98.05% |
| 2018 | 3.47 Million EUR | -6.53% |
| 2017 | 3.72 Million EUR | -31.35% |
| 2016 | 5.42 Million EUR | 35.03% |
| 2015 | 4.01 Million EUR | 44.91% |
| 2014 | 2.77 Million EUR | 1398.23% |
| 2013 | 184.93 Thousand EUR | 149.4% |
| 2012 | 74.15 Thousand EUR | -94.55% |
| 2011 | 1.36 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 9.28 Million EUR | 0.0% |
| 2023 FY | 30.05 Million EUR | 529.36% |
| 2023 Q4 | 32.91 Million EUR | 0.0% |
| 2023 Q2 | 3.29 Million EUR | 0.0% |
| 2022 Q4 | 3.44 Million EUR | 0.0% |
| 2022 FY | 4.77 Million EUR | 47660.0% |
| 2022 Q2 | 1.32 Million EUR | 0.0% |
| 2021 Q4 | 1.32 Million EUR | 0.0% |
| 2021 FY | 10 Thousand EUR | -80.0% |
| 2021 Q2 | 10 Thousand EUR | 0.0% |
| 2020 Q4 | 13 Thousand EUR | 0.0% |
| 2020 Q2 | 37 Thousand EUR | 0.0% |
| 2020 FY | 50 Thousand EUR | -26.47% |
| 2019 Q2 | 37 Thousand EUR | 0.0% |
| 2019 Q4 | 31 Thousand EUR | 0.0% |
| 2019 FY | 68 Thousand EUR | -98.05% |
| 2018 Q4 | 1.41 Million EUR | 0.0% |
| 2018 FY | 3.47 Million EUR | -6.53% |
| 2018 Q2 | 2.06 Million EUR | 0.0% |
| 2017 Q2 | 1.88 Million EUR | 0.0% |
| 2017 FY | 3.72 Million EUR | -31.35% |
| 2017 Q4 | 1.83 Million EUR | 0.0% |
| 2016 FY | 5.42 Million EUR | 35.03% |
| 2016 Q2 | 3.03 Million EUR | 0.0% |
| 2016 Q4 | 2.38 Million EUR | 0.0% |
| 2015 Q4 | 2.35 Million EUR | 0.0% |
| 2015 Q2 | 1.65 Million EUR | 0.0% |
| 2015 FY | 4.01 Million EUR | 44.91% |
| 2014 Q4 | 1.77 Million EUR | 0.0% |
| 2014 FY | 2.77 Million EUR | 1398.23% |
| 2014 Q2 | 997.39 Thousand EUR | 0.0% |
| 2013 Q3 | 46.23 Thousand EUR | -93.06% |
| 2013 Q2 | 666.45 Thousand EUR | 1341.47% |
| 2013 Q1 | 46.23 Thousand EUR | 0.0% |
| 2013 FY | 184.93 Thousand EUR | 149.4% |
| 2013 Q4 | 929.01 Thousand EUR | 1909.38% |
| 2012 Q3 | 18.53 Thousand EUR | 0.0% |
| 2012 Q1 | 18.53 Thousand EUR | 0.0% |
| 2012 Q4 | 46.23 Thousand EUR | 149.4% |
| 2012 FY | 74.15 Thousand EUR | -94.55% |
| 2012 Q2 | 18.53 Thousand EUR | 0.0% |
| 2011 Q3 | 340.07 Thousand EUR | 0.0% |
| 2011 Q2 | 340.07 Thousand EUR | 0.0% |
| 2011 Q1 | 340.07 Thousand EUR | 0.0% |
| 2011 FY | 1.36 Million EUR | 0.0% |
| 2011 Q4 | 18.53 Thousand EUR | -94.55% |
| 2010 Q4 | 340.07 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -547.802% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -550.465% |
| Adocia SA | 2.15 Million EUR | -1298.047% |
| Aelis Farma SA | 9.05 Million EUR | -231.986% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -853.919% |
| genOway Société anonyme | 20.04 Million EUR | -49.942% |
| IntegraGen SA | 12.53 Million EUR | -139.746% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -9918.198% |
| Neovacs S.A. | 533.41 Thousand EUR | -5535.044% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -1687.555% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -151738.755% |
| Sensorion SA | 4.74 Million EUR | -533.725% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -10043.387% |
| TME Pharma N.V. | 17 Thousand EUR | -176711.765% |
| Valbiotis SA | 4.73 Million EUR | -535.073% |
| TheraVet SA | 1.07 Million EUR | -2688.169% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -1569.889% |
| argenx SE | 1.13 Billion EUR | 97.35% |
| BioSenic S.A. | 543 Thousand EUR | -5435.543% |
| Celyad Oncology SA | 102 Thousand EUR | -29368.627% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 87.461% |
| Genfit S.A. | 28.56 Million EUR | -5.227% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -1340.249% |
| Innate Pharma S.A. | 51.9 Million EUR | 42.086% |
| Inventiva S.A. | 17.47 Million EUR | -71.986% |
| MaaT Pharma SA | 2.22 Million EUR | -1249.102% |
| MedinCell S.A. | 9.16 Million EUR | -228.144% |
| Onward Medical N.V. | 532 Thousand EUR | -5550.0% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -111.801% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -1249.708% |
| Oxurion NV | 263 Thousand EUR | -11328.897% |
| Pharming Group N.V. | 245.31 Million EUR | 87.747% |
| Poxel S.A. | 1.98 Million EUR | -1417.314% |
| GenSight Biologics S.A. | 1.26 Million EUR | -2272.376% |
| Transgene SA | 1.18 Million EUR | -2438.682% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.428% |
| Valneva SE | 153.71 Million EUR | 80.445% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 930.331% |